Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient ...

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study of uliledlimab ...

Q3 2024 Earnings Call Transcript November 13, 2024 Mersana Therapeutics, Inc. misses on earnings expectations. Reported EPS ...

esmo group (esmo), a leading global full-service systems integrator, developer, and supplier of innovative and advanced automation solutions, is proud to announce the launch of its latest product—the ...

In October 2024, we provided updated results from our IMMUNOCERV Phase 2 clinical trial in locally advanced cervical cancer patients treated with Versamune ® HPV and chemoradiotherapy presented at the ...

AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US ...

Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology -- Two new ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

Acrivon Therapeutics, Inc. ("Acrivon” or "Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company ...

Massive revenue growth, surging margins, and groundbreaking cancer breakthroughs--Natera's unstoppable rise is turning heads ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...